Pasadena, California Clinical Trials

A listing of Pasadena, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 65 clinical trials
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

fitusiran
haemophilia a
bethesda assay
factor ix
hemophilia
Investigational Site Number 8400002
 (8.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
None

University of Southern California
 (7.7 away) Contact site
  • 0 views
  • 19 May, 2025
  • +19 other locations
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MPP2+ Recurrent or Progressive Glioblastoma

This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Vaccines made from a gene-modified virus may …

tumor cells
measurable disease
immunohistochemistry
karnofsky performance status
expression by immunohistochemistry
City of Hope Medical Center
 (9.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Evaluate the safety and tolerability of AMG 509 in adult subjects and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

castration-resistant prostate cancer
cancer
dexamethasone
neutrophil count
metastasis
Research Site
 (9.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +3 other locations
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC.

measurable disease
castration-resistant prostate cancer
cancer
metastasis
metastatic disease
City of Hope Comprehensive Cancer Center
 (9.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +2 other locations
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

This phase II trial studies how well total marrow and lymphoid irradiation works as a conditioning regimen before hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute leukemia. Total body irradiation can lower the relapse rate but has some fatal side effects such as irreversible damage to normal internal …

cancer
fludarabine
forced vital capacity
lymphoblastic leukemia
chromosomal abnormalities
City of Hope Medical Center
 (9.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

anticancer agents
solid tumors
cancer
hematopoietic growth factors
non-hodgkin lymphoma
City of Hope Comprehensive Cancer Center
 (9.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

measurable disease
nf2 gene
multiple meningiomas
neutrophil count
crizotinib
Univ of California @ Los Angeles (Site 325)
 (8.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
A Study to Evaluate the Safety Pharmacokinetics and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

solid tumour
kras g12c mutation
kras
ki-ras
metastatic malignant solid tumor
City of Hope Comprehensive Cancer Center
 (9.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.

carcinoma
karnofsky performance status
renal cell carcinoma
Research Site 2
 (9.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations